← All trials
NCT05128643
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2021
- Primary completion
- Apr 12, 2022
- Completion date
- Oct 12, 2022
- First posted
- Nov 22, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 300
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
- Government of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.